Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron plus tamsulosin for BPH-related LUTS/OAB
ChiCTR2100047530Phase 4Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of mirabegron and tamsulosin in benign prostatic hyperplasia (BPH) and overactive bladder (OAB) (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoints: Overactive bladder symptom score at 12 weeks and International Prostate Symptom Score at 12 weeks. Started Jun 2021; status: recruiting.
02
Drugs
mirabegrontamsulosin
03
Conditions
benign prostatic hyperplasia (BPH)overactive bladder (OAB)
Beyond the preview
Go deeper on ChiCTR2100047530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047530.